Pharvaris Acquired | Healthcare M&A Deal

Pharvaris has completed the acquisition of Pharvaris, a pharmacy business in Switzerland, for $132.3 million. Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists for hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH). The company’s oral pharmacy pipeline targets unmet needs in bradykinin-mediated diseases and supports continued clinical and commercialization planning. This other acquisition closed a $132.3 million underwritten offering of ordinary shares, including full exercise of the underwriters’ option to purchase additional shares, with gross proceeds of about $132.3 million before underwriting discounts and commissions.